In relation to our findings here, it will be interesting to measure the concentration and activity of PAK1, as well as gastrins and progastrin in tumors from CRC patients since we and others have reported that circulating gastrins and progastrin were increased in CRC patients (Do et al. 2012; Paterson et al. 2014). Here, PAK1 is linked to colorectal carcinoma.